📈 在 COMPANION-002 2/3 期试验中，Tovecimig 联合 paclitaxel 相比单用 paclitaxel，改善了既往经治晚期胆道癌的 ORR。@myESMO #ESMO2026 #oncology
完整报道 ➡️：https://www.onclive.com/view/tovecimig-plus-paclitaxel-improves-orr-vs-paclitaxel-alone-in-biliary-tract-cancer
57 浏览 · 1 赞 · 1 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：OncLive.com · x.com